Medical Pharmacology: Chapter 3: Pharmacodynamics -- Module 8: Advanced Pharmacodynamic Concepts — Hysteresis, Indirect Response and Drug Interactions

Chapter 3: Pharmacodynamics — Module 8: Advanced Pharmacodynamic Concepts — Hysteresis, Indirect Response and Drug Interactions

1. Which of the following best describes the term "hysteresis" as used in clinical pharmacodynamics?

A) The phenomenon in which a drug's maximum effect exceeds the predicted Emax due to receptor reserve amplification of the stimulus-response relationship
B) The progressive reduction in drug effect with repeated dosing, requiring dose escalation to maintain the same therapeutic response
C) The temporal disconnect between plasma drug concentration and pharmacological effect, producing a loop when effect is plotted against plasma concentration over time
D) The delay between oral drug administration and first appearance of drug in the systemic circulation, caused by absorption lag time
E) The difference between the drug concentration that produces 50% of maximum effect and the concentration that occupies 50% of receptors, reflecting receptor reserve

ANSWER: C

Rationale:

Hysteresis in pharmacodynamics refers to the phenomenon in which the relationship between plasma drug concentration and pharmacological effect is not a simple direct proportion but instead traces a loop when plotted over time. If effect is plotted on the y-axis against plasma concentration on the x-axis at multiple time points after a dose, a loop is produced -- the effect at a given plasma concentration differs depending on whether concentrations are rising or falling. This occurs whenever there is a temporal disconnect between the plasma compartment and the site of drug action (the biophase or effect compartment). The loop direction (clockwise or counterclockwise) carries pharmacokinetic and pharmacodynamic information. Counterclockwise hysteresis indicates that effect lags behind plasma concentration -- the drug must distribute to the effect site before producing its peak effect. Clockwise hysteresis indicates that effect is maximal early relative to plasma concentration and diminishes despite maintained plasma levels, consistent with tolerance or active metabolite depletion.

Option A: Option A is incorrect -- receptor reserve amplification explains why EC50 (the concentration producing 50% of maximum effect) is lower than Kd but does not produce hysteresis.
Option B: Option B is incorrect -- progressive tolerance with repeated dosing is a distinct pharmacodynamic phenomenon, not the definition of hysteresis.
Option D: Option D is incorrect -- absorption lag time describes pharmacokinetics of drug appearance in plasma, not the plasma-effect relationship.
Option E: Option E is incorrect -- the difference between EC50 and Kd reflects receptor reserve, a distinct concept from hysteresis.

2. The effect compartment model was developed to address which pharmacodynamic problem?

A) The inability of simple Emax models to describe drugs with Hill coefficients greater than 1, where the concentration-effect curve is steeper than a hyperbola
B) The mathematical problem of fitting dose-response curves to drugs with multiple active metabolites that each contribute independently to the observed effect
C) The problem of receptor reserve amplification causing EC50 to be lower than Kd -- the effect compartment model corrects for spare receptor amplification in estimating true receptor affinity
D) The difficulty of modeling drugs with irreversible receptor binding, where effect duration outlasts the plasma concentration-time profile because receptors cannot be reactivated
E) The disconnect between plasma concentration and pharmacological effect caused by distributional delay as drug moves from plasma to the biophase; the effect compartment is a hypothetical compartment linked to plasma by a first-order rate constant (ke0) that describes the rate of plasma-biophase equilibration

ANSWER: E

Rationale:

The effect compartment model, introduced by Sheiner and colleagues, addresses the fundamental pharmacodynamic problem of hysteresis -- the observation that pharmacological effect does not track plasma concentration directly but lags behind it. The model postulates a hypothetical effect compartment (the biophase) that is kinetically distinct from plasma. Drug moves from plasma into the effect compartment by a first-order process described by ke0 (the effect-site equilibration rate constant). The concentration in the effect compartment (Ce) drives the pharmacological effect according to an Emax or Hill equation. Because the effect compartment is assumed to be negligibly small (it does not meaningfully alter plasma pharmacokinetics), it is a purely pharmacodynamic construct. The ke0 parameter quantifies how rapidly drug equilibrates between plasma and effect site -- a large ke0 means rapid equilibration and minimal hysteresis; a small ke0 means slow equilibration and pronounced lag. This model allows accurate prediction of the time course of drug effect even when it diverges significantly from the plasma concentration-time profile.

Option A: Option A is incorrect -- steep concentration-effect relationships are modeled by the sigmoidal Emax (Hill) equation with n greater than 1, which is independent of the effect compartment concept.
Option B: Option B is incorrect -- multiple active metabolites require separate pharmacokinetic-pharmacodynamic models for each entity; the effect compartment model does not address multi-metabolite complexity.
Option C: Option C is incorrect -- receptor reserve explains the difference between EC50 and Kd but is a separate pharmacodynamic concept unrelated to the effect compartment model.
Option D: Option D is incorrect -- irreversible receptor binding requires dedicated irreversible binding models; the effect compartment model assumes reversible drug-receptor interaction.

3. Warfarin produces its anticoagulant effect through which mechanism that places it in the category of an "indirect response" drug?

A) Warfarin inhibits vitamin K epoxide reductase, suppressing synthesis of vitamin K-dependent clotting factors (II, VII, IX, X); the anticoagulant effect emerges slowly as existing clotting factors are eliminated through normal turnover -- the time course of effect is determined not by warfarin's pharmacokinetics but by the half-lives of the clotting factors themselves, with factor VII (half-life 6 hours) falling first and factor II (half-life 60-72 hours) last
B) Warfarin directly blocks thrombin activity in the coagulation cascade, and the INR rise after initiation reflects slow distribution of warfarin into the hepatic parenchyma where thrombin is produced
C) Warfarin is a prodrug that requires hepatic bioactivation to its active S-enantiomer; the delay in anticoagulant effect reflects the time required for CYP2C9-mediated bioactivation to accumulate sufficient active drug at the site of action
D) Warfarin binds the von Willebrand factor receptor on platelets, and the anticoagulant effect lag reflects the slow turnover of platelet receptor complexes in the circulation
E) Warfarin crosses into the cell nucleus and directly suppresses clotting factor gene transcription through a nuclear receptor mechanism; the delay in anticoagulant effect reflects the time required for nuclear receptor complex formation and transcriptional repression

ANSWER: A

Rationale:

Warfarin is the classic example of an indirect pharmacodynamic response drug. It does not directly block coagulation but rather inhibits vitamin K epoxide reductase (VKOR), the enzyme that recycles vitamin K epoxide to the active reduced form needed as a cofactor for gamma-carboxylation of clotting factors II, VII, IX, and X. As VKOR is inhibited, no new active clotting factors can be synthesized. However, the existing clotting factors in circulation must be cleared through their normal biological half-lives before the anticoagulant effect becomes clinically evident. Factor VII, with the shortest half-life of approximately 6 hours, falls first -- producing an early rise in the prothrombin time. Factor II (prothrombin), with a half-life of 60-72 hours, is the last to fall and is the major determinant of sustained anticoagulation. This explains why full therapeutic anticoagulation with warfarin requires 4-5 days even though warfarin achieves steady-state plasma concentrations within 1-2 days. The time course of effect is governed by clotting factor turnover, not warfarin pharmacokinetics -- the defining characteristic of an indirect response model.

Option B: Option B is incorrect -- warfarin does not directly inhibit thrombin; it suppresses production of vitamin K-dependent clotting factors.
Option C: Option C is incorrect -- warfarin is administered as a racemic mixture; the S-enantiomer is more potent and is primarily metabolized by CYP2C9, but warfarin does not require bioactivation; both enantiomers are pharmacologically active as administered.
Option D: Option D is incorrect -- warfarin does not act on platelets or von Willebrand factor; it acts in the liver on vitamin K recycling.
Option E: Option E is incorrect -- warfarin inhibits an enzyme (VKOR) in the vitamin K recycling pathway, not a nuclear receptor; its mechanism is enzymatic inhibition, not transcriptional repression.

4. Which of the following correctly describes the concept of a pharmacodynamic biomarker?

A) A laboratory measurement that directly reflects the pharmacokinetic disposition of a drug -- specifically, a measurement of plasma drug concentration that confirms the drug is present at a therapeutic level
B) A genetic polymorphism in a drug-metabolizing enzyme or drug transporter that predicts interindividual variability in drug exposure -- a pharmacogenomic marker used to individualize dosing before therapy is initiated
C) A standardized clinical outcome measure (mortality, hospitalization rate, disease progression) used in phase III trials to determine whether a drug produces a meaningful clinical benefit in the target population
D) A measurement that directly reflects receptor or pathway activity in response to a drug -- ideally positioned between the drug's mechanism of action and the clinical outcome -- used to demonstrate target engagement, guide dose selection, and predict clinical benefit; validated biomarkers can serve as surrogate endpoints when they reliably predict clinical outcomes
E) A measurement of receptor density or affinity obtained from tissue biopsy or PET (positron emission tomography) imaging, used exclusively in early phase I studies to confirm that the drug is reaching its intended molecular target in tissue

ANSWER: D

Rationale:

A pharmacodynamic biomarker is a measurable biological variable that reflects the activity of a drug at its target -- it sits between the drug's mechanism of action and the clinical outcome on the pharmacological causal chain. Examples include HbA1c (glycated hemoglobin) as a biomarker of glycemic control for antidiabetic drugs, LDL cholesterol as a biomarker of statin activity, INR as a biomarker of warfarin anticoagulation, and CD4 count or viral load as biomarkers of antiretroviral efficacy. Pharmacodynamic biomarkers serve multiple roles: they confirm target engagement (proving the drug is doing what it is supposed to do at the molecular level), guide dose selection (establishing the relationship between dose, exposure, and biological effect), and when validated, can serve as surrogate endpoints that predict clinical benefit. The distinction between a biomarker and a surrogate endpoint is important: a surrogate endpoint is a validated biomarker that has been shown to reliably predict a meaningful clinical outcome. Not all biomarkers are validated surrogates -- the CAST (Cardiac Arrhythmia Suppression Trial) illustrated the danger of assuming that a biomarker response automatically predicts clinical benefit.

Option A: Option A is incorrect -- a plasma drug concentration measurement is a pharmacokinetic measurement, not a pharmacodynamic biomarker; it measures drug exposure, not drug effect.
Option B: Option B is incorrect -- a genetic polymorphism predicting drug metabolism is a pharmacogenomic marker, distinct from a pharmacodynamic biomarker.
Option C: Option C is incorrect -- mortality, hospitalization rate, and disease progression are clinical endpoints or outcomes, not biomarkers; they represent the ultimate measure of clinical benefit rather than an intermediate biological signal.
Option E: Option E is incorrect -- while receptor occupancy measurements by PET imaging are one type of pharmacodynamic biomarker, defining all biomarkers as requiring tissue biopsy or PET and restricting them to phase I is incorrect; pharmacodynamic biomarkers are used throughout drug development and clinical practice.

5. The CAST trial demonstrated a critical limitation of biomarker-based drug development. What was the key finding and its pharmacodynamic lesson?

A) Encainide and flecainide failed to suppress ventricular ectopic beats despite achieving plasma concentrations within the therapeutic range, demonstrating that the pharmacodynamic biomarker response to antiarrhythmic drugs is unpredictable and cannot be used to guide dosing
B) Encainide and flecainide effectively suppressed ventricular ectopic beats (the pharmacodynamic biomarker) in post-MI patients, but patients receiving these drugs had significantly higher mortality than those receiving placebo -- demonstrating that a positive biomarker response does not guarantee clinical benefit and may mask harm; suppression of a surrogate endpoint can occur simultaneously with worsening of the clinical outcome the surrogate was assumed to represent
C) Encainide and flecainide reduced mortality in post-MI patients with ventricular ectopy, validating ventricular ectopic beat suppression as a reliable surrogate endpoint for antiarrhythmic drug development
D) Encainide and flecainide produced equivalent ventricular ectopy suppression to amiodarone but with superior mortality outcomes, establishing that pharmacodynamic biomarker equivalence predicts clinical outcome equivalence between antiarrhythmic drug classes
E) The CAST trial demonstrated that antiarrhythmic drug plasma concentration monitoring was insufficient to prevent toxicity, establishing the need for pharmacodynamic biomarker monitoring to guide antiarrhythmic therapy

ANSWER: B

Rationale:

The Cardiac Arrhythmia Suppression Trial (CAST) is one of the most important cautionary examples in the history of clinical pharmacology. The premise was logical: ventricular ectopic beats after myocardial infarction (MI) are associated with increased mortality; antiarrhythmic drugs suppress ectopic beats; therefore suppressing ectopic beats should reduce mortality. Encainide and flecainide were highly effective at suppressing the pharmacodynamic biomarker -- ventricular ectopy fell substantially in treated patients. When CAST was stopped early, however, it was because patients receiving these drugs had approximately 3.5 times the mortality of those receiving placebo, despite -- or perhaps because of -- the effective ectopy suppression. The pharmacodynamic lesson is fundamental: a drug that moves a biomarker in the desired direction does not necessarily produce clinical benefit. The biomarker (ectopy suppression) was not a validated surrogate for the clinical endpoint (mortality). In fact, the mechanism by which encainide and flecainide suppressed ectopy -- sodium channel blockade -- also increased the risk of fatal proarrhythmia in post-MI myocardium. CAST fundamentally changed how surrogate endpoints are validated in cardiology and drug development broadly.

Option A: Option A is incorrect -- encainide and flecainide were effective at suppressing ectopic beats; the pharmacodynamic biomarker response was positive. The problem was not failure of biomarker suppression but failure of biomarker suppression to predict clinical benefit.
Option C: Option C is incorrect -- the opposite of the CAST finding; mortality was increased, not reduced, in the treatment groups.
Option D: Option D is incorrect -- CAST did not compare encainide/flecainide to amiodarone; no mortality advantage for these drugs was demonstrated.
Option E: Option E is incorrect -- CAST's lesson was about surrogate endpoint validity, not about concentration monitoring adequacy.

6. Which of the following special populations demonstrates increased CNS sensitivity to opioids and benzodiazepines at standard plasma concentrations, representing a pharmacodynamic rather than pharmacokinetic alteration?

A) Pediatric patients under age 5, whose increased hepatic CYP3A4 activity accelerates benzodiazepine metabolism, producing paradoxically low plasma concentrations at standard doses that are misinterpreted as increased CNS sensitivity
B) Post-surgical patients in the immediate recovery period, whose reduced CNS blood flow from residual anesthetic effects lowers drug delivery to the brain, paradoxically producing enhanced apparent sensitivity through slow receptor equilibration
C) Patients with hepatic encephalopathy, who demonstrate markedly increased CNS sensitivity to benzodiazepines and opioids at plasma concentrations that produce minimal effect in patients with normal hepatic function -- reflecting increased GABAergic tone, upregulation of neurosteroid-sensitive GABA-A receptor subunits, and accumulation of endogenous benzodiazepine-like substances in the CNS
D) Patients with chronic renal failure, whose impaired renal drug clearance raises benzodiazepine plasma concentrations above the measured level through redistribution of protein-bound drug from uremic plasma proteins
E) Patients on chronic SSRI therapy, whose upregulated serotonin receptors interact with opioid mu receptors through receptor heteromerization, amplifying opioid CNS effects at standard plasma concentrations

ANSWER: C

Rationale:

Hepatic encephalopathy is a classic example of pharmacodynamic alteration -- increased CNS drug sensitivity that is not explained by elevated plasma drug concentrations. Patients with hepatic encephalopathy are exquisitely sensitive to benzodiazepines and opioids, sometimes developing profound CNS depression at doses that produce minimal sedation in patients with normal liver function. The pharmacodynamic mechanisms are several: chronic liver failure increases GABAergic neurotransmission through accumulation of ammonia and glutamine, which alter GABA-A receptor function; upregulation of neurosteroid-sensitive GABA-A receptor subunits (particularly those containing alpha4 or delta subunits) increases receptor sensitivity to endogenous and exogenous GABAergic agents; and endogenous benzodiazepine-like substances (including diazepam-binding inhibitor fragments and plant-derived benzodiazepine compounds from dietary sources that accumulate in liver failure) further sensitize the receptor. The consequence is that standard doses of benzodiazepines or opioids may precipitate or worsen hepatic encephalopathy. This is a pharmacodynamic effect -- the CNS responds more to the same drug concentration -- not a pharmacokinetic one.

Option A: Option A is incorrect -- pediatric CYP3A4 activity is actually lower in infancy and increases with age; increased metabolism produces lower, not higher, concentrations, and this is a pharmacokinetic, not pharmacodynamic, phenomenon.
Option B: Option B is incorrect -- reduced cerebral blood flow would slow drug delivery to the CNS but does not constitute pharmacodynamic sensitization; this describes a distributional phenomenon.
Option D: Option D is incorrect -- uremic protein binding changes are pharmacokinetic and affect free drug fraction; this is not the mechanism of pharmacodynamic sensitization described.
Option E: Option E is incorrect -- SSRI-mediated serotonin receptor upregulation and mu-opioid receptor heteromerization is not an established mechanism of increased CNS opioid sensitivity at standard plasma concentrations.

7. In the elderly, beta-adrenergic receptor responsiveness is reduced compared to younger adults. Which of the following correctly describes the pharmacodynamic consequence of this age-related change?

A) Elderly patients require lower doses of beta-agonists because reduced receptor responsiveness means the same plasma concentration produces greater effect through compensatory receptor sensitization
B) Elderly patients show increased sensitivity to beta-agonists because age-related reduction in receptor density is accompanied by upregulation of downstream Gs protein coupling, amplifying the signal from each remaining receptor
C) Beta-receptor responsiveness is unchanged in the elderly -- the apparent reduction in beta-agonist effect is entirely explained by pharmacokinetic changes in drug absorption and distribution with aging
D) Elderly patients require higher doses of beta-agonists specifically because aging upregulates beta-receptor density through a compensatory mechanism, increasing the number of receptors that must be occupied to produce the same effect
E) Elderly patients show a reduced maximum heart rate and inotropic response to beta-agonists and reduced bronchoprotective response to beta-2 agonists; the Emax of the beta-adrenergic system is reduced; this reflects age-related post-receptor changes -- reduced Gs protein coupling efficiency, decreased adenylyl cyclase activity, and reduced downstream cAMP (cyclic adenosine monophosphate) signaling -- rather than simply a reduction in receptor density

ANSWER: E

Rationale:

Age-related reduction in beta-adrenergic responsiveness is a well-documented pharmacodynamic change that affects the clinical management of elderly patients across multiple therapeutic contexts. The change is primarily post-receptor: while receptor density does decline modestly with age, the dominant mechanism is reduced efficiency of receptor-Gs protein coupling and decreased adenylyl cyclase activity downstream, resulting in less cAMP generation per unit of receptor occupancy. The pharmacodynamic consequence is a reduced Emax -- elderly patients cannot achieve the same maximum heart rate, inotropic response, or bronchodilation as younger patients even at saturating beta-agonist concentrations. This is clinically relevant in several ways: the maximum heart rate response to exercise is lower in the elderly, the inotropic reserve for beta-agonist support in heart failure is reduced, and the bronchoprotective response to salbutamol in asthma or COPD may be attenuated. It also means that beta-blocker therapy in the elderly produces a smaller reduction in heart rate per dose than in younger patients, and the heart rate target for rate control in atrial fibrillation may be harder to achieve.

Option A: Option A is incorrect -- reduced receptor responsiveness does not produce compensatory sensitization; the Emax is reduced, not the EC50.
Option B: Option B is incorrect -- reduced receptor density is not accompanied by compensatory Gs upregulation; both receptor density and coupling efficiency decline with age.
Option C: Option C is incorrect -- beta-receptor responsiveness is genuinely reduced in the elderly through pharmacodynamic mechanisms; this is not solely a pharmacokinetic artifact.
Option D: Option D is incorrect -- beta-receptor density does not increase with age through a compensatory mechanism; receptor density declines modestly, and the primary pharmacodynamic change is post-receptor.

8. Which of the following drug pairs is an example of pharmacodynamic synergism -- a combined effect greater than the sum of the individual effects -- through sequential blockade of the same biochemical pathway?

A) Trimethoprim and sulfamethoxazole (TMP-SMX) -- trimethoprim inhibits dihydrofolate reductase (DHFR), blocking conversion of dihydrofolate to tetrahydrofolate, while sulfamethoxazole inhibits dihydropteroate synthase, blocking an earlier step in folate synthesis; by blocking two sequential steps in the bacterial folate synthesis pathway, the combination produces synergistic antibacterial activity greater than either drug alone
B) Warfarin and aspirin -- warfarin reduces clotting factor synthesis while aspirin irreversibly inhibits platelet cyclooxygenase; both reduce thrombotic risk through complementary mechanisms but the combination is additive for antithrombotic effect and synergistic only for bleeding risk
C) Metoprolol and amlodipine -- metoprolol reduces heart rate and amlodipine reduces peripheral vascular resistance; their antihypertensive effects are additive rather than synergistic because they act on pharmacologically independent targets without mutual amplification
D) Furosemide and hydrochlorothiazide -- both drugs are loop and thiazide diuretics respectively that inhibit sodium reabsorption at different nephron segments; their diuretic effects are additive at standard doses but become synergistic only when sequential nephron blockade amplifies sodium delivery to the collecting duct
E) Morphine and acetaminophen -- morphine activates mu-opioid receptors and acetaminophen inhibits central prostaglandin synthesis; their analgesic effects are additive rather than synergistic because they act through completely independent mechanisms that do not amplify each other at the receptor level

ANSWER: A

Rationale:

Trimethoprim and sulfamethoxazole represent the pharmacological archetype of synergism through sequential pathway blockade. Bacterial folate synthesis proceeds through a series of enzymatic steps: para-aminobenzoic acid (PABA) is converted to dihydropteroate by dihydropteroate synthase (the target of sulfamethoxazole), which is then processed further to dihydrofolate and then to tetrahydrofolate by DHFR (the target of trimethoprim). By blocking two sequential steps in the same essential pathway, each drug amplifies the effect of the other -- sulfamethoxazole depletes the substrate that DHFR would otherwise process, while trimethoprim blocks the step immediately downstream. The result is synergistic inhibition of bacterial folate metabolism at concentrations of each drug that individually might be only bacteriostatic; together, the combination is bactericidal in many organisms. This is sequential or dual pathway blockade synergism.

Option B: Option B is incorrect -- warfarin and aspirin act through pharmacologically complementary but mechanistically independent pathways; their antithrombotic effects are additive rather than synergistic in the strict pharmacodynamic sense.
Option C: Option C is incorrect -- metoprolol and amlodipine have complementary mechanisms that produce additive antihypertensive effects; this is an example of pharmacodynamic additivity, not synergism.
Option D: Option D is incorrect -- furosemide and hydrochlorothiazide do produce synergistic diuresis in some clinical contexts through sequential nephron blockade, but the mechanism is not as clean as TMP-SMX sequential pathway blockade; TMP-SMX remains the classic teaching example.
Option E: Option E is incorrect -- morphine and acetaminophen produce additive rather than synergistic analgesia; independent mechanisms do not automatically produce synergism.

9. Counterclockwise (anti-clockwise) hysteresis is the most commonly observed type. Which of the following correctly identifies a drug that exhibits counterclockwise hysteresis and correctly explains the mechanism?

A) Warfarin -- counterclockwise hysteresis arises because warfarin rapidly achieves effect-site concentrations in the hepatocyte, but the anticoagulant effect lags because existing clotting factors must be cleared through normal turnover before the INR rises; this is a distributional lag from plasma to hepatic parenchyma
B) Propranolol -- counterclockwise hysteresis arises because propranolol is a cardioselective beta-blocker that preferentially distributes to cardiac tissue; the lag between plasma concentration and heart rate reduction reflects slow redistribution from skeletal muscle to myocardium
C) Digoxin -- counterclockwise hysteresis arises because digoxin directly activates cardiac sodium pumps in the plasma compartment before distributing to myocardial tissue, producing early toxicity followed by delayed therapeutic effect
D) Morphine -- counterclockwise hysteresis arises because morphine must cross the blood-brain barrier (BBB) and equilibrate into the CNS biophase before producing its analgesic and respiratory depressant effects; at any given plasma morphine concentration, the effect is greater when concentrations are falling (after distribution equilibrium has been reached) than when they are rising (before full CNS equilibration), producing a counterclockwise loop on the concentration-effect plot
E) Salbutamol -- counterclockwise hysteresis arises because salbutamol undergoes first-pass metabolism to an active metabolite that accumulates during prolonged infusion; the rising metabolite concentration at falling parent drug levels maintains bronchodilation beyond what plasma salbutamol alone would predict

ANSWER: D

Rationale:

Morphine is a well-characterized example of counterclockwise hysteresis. After IV administration, morphine plasma concentrations peak rapidly but the analgesic and respiratory depressant effects peak later -- typically 15-30 minutes after the plasma peak -- because morphine must cross the blood-brain barrier and distribute into the CNS biophase. Morphine's relatively low lipophilicity compared to fentanyl means it crosses the BBB more slowly, producing a pronounced distributional lag. When effect is plotted against plasma concentration over time, a counterclockwise loop is produced: at a given plasma concentration, the effect is smaller when concentrations are rising (early, before CNS equilibration) than when concentrations are falling (later, after equilibration). This counterclockwise hysteresis is quantified by the effect compartment model using ke0, which for morphine is relatively small, reflecting slow plasma-CNS equilibration. This pharmacodynamic characteristic is clinically important: after an IV morphine dose, the peak respiratory depressant effect occurs well after the peak plasma concentration, and clinical monitoring must account for this lag.

Option A: Option A is incorrect -- warfarin's delayed INR response reflects indirect pharmacodynamics (clotting factor turnover), not distributional lag to the hepatocyte; the warfarin hysteresis loop is clockwise because effect outlasts the plasma concentration as clotting factors recover slowly.
Option B: Option B is incorrect -- propranolol is not cardioselective (metoprolol and bisoprolol are); and propranolol's hysteresis, if present, does not arise from redistribution between muscle and myocardium.
Option C: Option C is incorrect -- digoxin does exhibit hysteresis, but it arises from distributional lag from plasma to myocardial tissue, not from direct plasma compartment activation; and digoxin toxicity does not precede therapeutic effect in the manner described.
Option E: Option E is incorrect -- salbutamol does not have a clinically significant active metabolite that accumulates during infusion and maintains bronchodilation beyond plasma levels.

10. Which of the following correctly describes the pharmacodynamic interaction between a beta-agonist (salbutamol) and a non-selective beta-blocker (propranolol) when both are present simultaneously?

A) Pharmacokinetic antagonism -- propranolol inhibits CYP2D6-mediated salbutamol metabolism, raising salbutamol plasma concentrations to levels that overwhelm propranolol's receptor blockade, producing apparent agonism despite the presence of the antagonist
B) Functional (physiological) antagonism -- salbutamol and propranolol act at the same receptor (beta-2 adrenergic receptor) through opposing mechanisms; salbutamol is an agonist and propranolol is a competitive antagonist at this receptor; the net effect depends on the relative concentrations and affinities of both drugs at the receptor, with high propranolol concentrations shifting the salbutamol dose-response curve rightward in a manner reversible by increasing salbutamol concentration
C) Chemical antagonism -- propranolol binds salbutamol in plasma, forming an inactive complex that prevents salbutamol from reaching its receptor; the degree of antagonism depends on the relative plasma concentrations and binding affinities of the two molecules
D) Pharmacokinetic synergism -- propranolol reduces hepatic blood flow through its negative inotropic effect, reducing salbutamol's first-pass hepatic metabolism and raising salbutamol bioavailability, producing greater-than-expected bronchodilation at standard salbutamol doses
E) Irreversible antagonism -- propranolol permanently occupies beta-2 receptors through covalent modification, and salbutamol cannot displace it regardless of concentration; the antagonism is overcome only by synthesis of new beta-2 receptors over 24-48 hours

ANSWER: B

Rationale:

The interaction between salbutamol and propranolol at the beta-2 adrenergic receptor is the textbook example of competitive pharmacodynamic antagonism -- correctly termed functional or physiological antagonism when it occurs at the same receptor through opposing actions. Salbutamol is a selective beta-2 agonist; propranolol is a non-selective beta-1 and beta-2 antagonist. At the beta-2 receptor, propranolol competes with salbutamol for the same binding site. Propranolol's antagonism is competitive and reversible: it shifts the salbutamol dose-response curve to the right (increases the EC50) without reducing the maximum effect (Emax) -- the Emax can be restored by increasing salbutamol concentration sufficiently to overcome propranolol's occupancy. This is pharmacodynamic competitive antagonism. The clinical consequence is that propranolol blocks salbutamol's bronchodilatory effect, which is dangerous in asthmatic patients -- propranolol is contraindicated in asthma precisely because it competitively antagonizes endogenous and exogenous beta-2 agonism in the airways. The correct pharmacodynamic term for this type of interaction is competitive antagonism at a shared receptor, also described as direct pharmacodynamic antagonism.

Option A: Option A is incorrect -- propranolol does not inhibit CYP2D6-mediated salbutamol metabolism in a clinically significant way; salbutamol is not primarily a CYP2D6 substrate, and pharmacokinetic antagonism refers to a different mechanism.
Option C: Option C is incorrect -- propranolol and salbutamol do not form an inactive plasma complex; chemical antagonism refers to direct chemical inactivation (such as protamine neutralizing heparin), not receptor competition.
Option D: Option D is incorrect -- while propranolol does reduce cardiac output and potentially hepatic blood flow, this does not produce clinically significant pharmacokinetic synergism with salbutamol; this is not the mechanism of their interaction.
Option E: Option E is incorrect -- propranolol is a reversible competitive antagonist, not an irreversible covalent modifier of beta receptors; its antagonism is fully reversible and concentration-dependent. ANSWER KEY: Q1=C Q2=E Q3=A Q4=D Q5=B Q6=C Q7=E Q8=A Q9=D Q10=B